These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1086 related articles for article (PubMed ID: 30339501)

  • 1. The intimate relationship between gut microbiota and cancer immunotherapy.
    Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
    Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity.
    Baiden-Amissah REM; Tuyaerts S
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31340438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota Manipulated to Enhance Immunity.
    Cancer Discov; 2019 Jul; 9(7):822. PubMed ID: 31072874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
    Hou F; Pan Z; Yang R; Zhi F; Bi Y
    J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 7. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
    Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
    Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
    Kim E; Ahn H; Park H
    Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The gut microbiota and immune checkpoint inhibitors.
    Humphries A; Daud A
    Hum Vaccin Immunother; 2018; 14(9):2178-2182. PubMed ID: 29494275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and clinical implications of immune checkpoint blockade in human cancer.
    Kim HD; Park SH
    Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
    Botticelli A; Zizzari I; Mazzuca F; Ascierto PA; Putignani L; Marchetti L; Napoletano C; Nuti M; Marchetti P
    Oncotarget; 2017 Jan; 8(5):8890-8899. PubMed ID: 27806346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome modulates efficacy of immune checkpoint inhibitors.
    Yi M; Yu S; Qin S; Liu Q; Xu H; Zhao W; Chu Q; Wu K
    J Hematol Oncol; 2018 Mar; 11(1):47. PubMed ID: 29580257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications.
    Guven DC; Aktas BY; Simsek C; Aksoy S
    Future Oncol; 2020 Mar; 16(9):497-506. PubMed ID: 32100550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
    Wang Y; Wiesnoski DH; Helmink BA; Gopalakrishnan V; Choi K; DuPont HL; Jiang ZD; Abu-Sbeih H; Sanchez CA; Chang CC; Parra ER; Francisco-Cruz A; Raju GS; Stroehlein JR; Campbell MT; Gao J; Subudhi SK; Maru DM; Blando JM; Lazar AJ; Allison JP; Sharma P; Tetzlaff MT; Wargo JA; Jenq RR
    Nat Med; 2018 Dec; 24(12):1804-1808. PubMed ID: 30420754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
    Bazhin AV; Amedei A; Karakhanova S
    Front Immunol; 2018; 9():2878. PubMed ID: 30568661
    [No Abstract]   [Full Text] [Related]  

  • 17. Gut microbiota modulation of chemotherapy efficacy and toxicity.
    Alexander JL; Wilson ID; Teare J; Marchesi JR; Nicholson JK; Kinross JM
    Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):356-365. PubMed ID: 28270698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation.
    Meng Y; Sun J; Zhang G
    Crit Rev Oncol Hematol; 2024 Aug; 200():104403. PubMed ID: 38838927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
    Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
    Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.